P/E ratio for AstraZeneca (AZN)

P/E ratio history for AstraZeneca from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Bristol-Myers Squibb BMY	14.2	-55.48%	🇺🇸 USA
Pfizer PFE	13.4	-58.27%	🇺🇸 USA
Merck MRK	53.6	67.52%	🇺🇸 USA
GlaxoSmithKline GSK	9.55	-70.14%	🇬🇧 UK
Sanofi SNY	15.1	-52.68%	🇫🇷 France
Eli Lilly LLY	138	332.30%	🇺🇸 USA
Johnson & Johnson JNJ	10.9	-65.78%	🇺🇸 USA
Abbott Laboratories ABT	39.0	21.90%	🇺🇸 USA
Biogen BIIB	8.71	-72.77%	🇺🇸 USA
Novartis NVS	27.6	-13.88%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.